CAR-T Cell Immunotherapy in MUC1 Positive Solid Tumor
The purpose of this study is to evaluate the safety and effectiveness of CAR-T cell immunotherapy in patients with MUC1 positive relapsed or refractory solid tumor.
Malignant Glioma of Brain|Colorectal Carcinoma|Gastric Carcinoma
BIOLOGICAL: anti-MUC1 CAR-T cells
Adverse events attributed to the administration of the anti-MUC1 CAR-T cells, Determine the toxicity profile of the MUC1 targeted CAR-T cells with Common Toxicity Criteria for Adverse Effects (CTCAE) version 4.0., 2 years
Objective Response Rate, The objective response rate (ORR) is defined as the proportion of patients who achieve radiographic partial or complete response (PR or CR) according to the Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 guideline., Safety follow-up is 100 days from last CAR-T infusion.
The purpose of this study is to evaluate the safety and effectiveness of CAR-T cell immunotherapy in patients with MUC1 positive relapsed or refractory solid tumor.